Differential effects of PCSK9 inhibitors and statins on plasma ceramides in coronary artery disease.

ABSTRACT:

Background

While elevated plasma ceramides are independently associated with increased cardiovascular risk in patients with coronary artery disease (CAD), the impact of current lipid-modifying drugs on ceramides, remains under-researched. This study examines the effect of PCSK9 inhibitors on plasma ceramides in patients with CAD who had received statin therapy.

Methods

Comparing the effect of PCSK9i vs. statin on ceramide levels. The primary outcome was percent change in ceramide levels. Subgroup analyses were done to explore potential treatment effect differences.

Results

Among 292 patients (44% statin group, 56% PCSK9i group), baseline characteristics were broadly similar. PCSK9i use significantly reduced ceramide levels compared to statin therapy: Cer 16:0 decrease

SUBMITTER: Zhang L 

PROVIDER: S-EPMC12756028 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature